Plain-English translation of NCT06382818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Breast cancer patients typically receive the same radiation therapy regardless of their individual risk factors. This trial is testing a personalized approach to radiation therapy that matches the intensity and type of treatment to each patient's specific risk of cancer coming back and their individual risk of developing side effects from radiation. By doing this, doctors hope to reduce unnecessary treatment for lower-risk patients while ensuring adequate treatment for those at higher risk.
Currently, most breast cancer patients receive standard radiation therapy without considering their personal risk factors. This trial exists because research suggests that some patients could receive less intensive treatment safely, while others need more aggressive therapy—and a one-size-fits-all approach may harm some patients or under-treat others.
You likely qualify if…
You likely don't qualify if…
After surgery and before starting radiation, you will have testing to determine your individual risk of cancer recurrence and your risk of developing side effects from radiation. Based on these results, you will be assigned to receive one of several personalized radiation therapy approaches—some patients may receive standard whole-breast radiation, while others may receive partial-breast radiation, brachytherapy, or radiation that includes the lymph nodes. Treatment typically takes 1–5 weeks depending on which approach is recommended for you. You will then be followed with regular visits to monitor how well the treatment worked and check for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment target
~854 participants
Started
March 2025
Primary completion
March 2028
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
MOUSSION AURORE
Institut du Cancer de Montpellier - Val d'Aurelle
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.